TEVA Form 144: Proposed sale of 17,295 shares

Teva Pharmaceutical Industries submitted a Form 144 notice reporting a proposed sale of 17,295 ordinary shares (ordinary shares to be sold through Citigroup Global Markets Inc.).

Rhea-AI Filing Summary

Teva Pharmaceutical Industries submitted a Form 144 notice reporting a proposed sale of 17,295 ordinary shares (ordinary shares to be sold through Citigroup Global Markets Inc.). The filing lists Richard Daniell as the selling person and shows earlier dispositions in the prior three months: 115,468 shares on 12/09/2025, 128,985 shares on 03/03/2026, and 91,345 shares on 03/04/2026, with corresponding gross proceeds included in the excerpt.

Insights

Insider Transactions Analyst

Form 144 lists a proposed sale of 17,295 shares and recent insider dispositions.

The filing identifies Citigroup Global Markets Inc. as the broker and shows the selling person as Richard Daniell. The excerpt records three prior dispositions: 115,468 shares (12/09/2025), 128,985 shares (03/03/2026), and 91,345 shares (03/04/2026), with listed gross proceeds.

These entries document reported sales activity; the actual timing and execution depend on broker handling and regulatory clearance. Subsequent SEC filings or broker confirmations would show settlement and final proceeds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the TEVA Form 144 disclose?

It discloses a proposed sale of 17,295 ordinary shares through Citigroup Global Markets Inc. The filing names Richard Daniell as the selling person and lists prior dispositions with exact share counts and gross proceeds.

Who is the selling party in the TEVA Form 144?

The selling person is Richard Daniell as shown in the excerpt. The record lists his address and identifies him as associated with Teva Pharmaceutical Industries Limited in the filing entries.

What recent insider sales are shown in the filing?

Three dispositions are shown: 115,468 shares on 12/09/2025, 128,985 shares on 03/03/2026, and 91,345 shares on 03/04/2026

Which broker is handling the proposed sale?

Citigroup Global Markets Inc. (address: 390 Greenwich Street, New York) is listed as the broker for the ordinary shares in the Form 144 excerpt provided.

Do the amounts in the Form 144 represent settled proceeds?

The filing shows gross proceeds tied to each past disposition (for example, 3,311,131.04 with one entry). Settlement status and net proceeds are not detailed in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001726096
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Daniell Richard
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP EUROPEAN COMMERCIAL

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	17295	547704.98	1149812898	03/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/05/2025	RESTRICTED SHARE AWARD EM	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			17295	03/05/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniell Richard TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	12/09/2025	115468	3311131.04
Daniell Richard TEVA PHARMACUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST TEL AVIV L3 6944020	ORDINARY SHARES	03/03/2026	128985	4173941.70
Daniell Richard 124 DVORA HANEVI'A ST. 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/04/2026	91345	2983515.95

144: Remarks and Signature

Remarks	SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES. THESE TRANSACTIONS WERE PART OF AN ESTABLISHED 10B51 PLAN ADOPTED IN NOVEMBER 2025
Date of Notice	03/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)